Cargando…

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy

PURPOSE: To assess the outcome of prostate cancer (PCa) patients diagnosed with oligorecurrent disease and treated with a first and a second PSMA (prostate-specific membrane antigen ligand) PET(positron-emission tomography)-directed radiotherapy (RT). PATIENTS AND METHODS: Thirty-two patients with o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henkenberens, Christoph, Oehus, Ann-Kathrin, Derlin, Thorsten, Bengel, Frank, Ross, Tobias L., Kuczyk, Markus A., Janssen, Stefan, Christiansen, Hans, von Klot, Christoph A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581615/ https://www.ncbi.nlm.nih.gov/pubmed/32399639 http://dx.doi.org/10.1007/s00066-020-01629-5

Ejemplares similares

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy
por: Vogel, Marco M. E., et al.
Publicado: (2020)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
por: Ohlendorf, Fiona, et al.
Publicado: (2021)

The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Derlin, Thorsten, et al.
Publicado: (2021)

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment
por: Bianchi, Lorenzo, et al.
Publicado: (2023)

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2022)

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
por: Werner, Rudolf A., et al.
Publicado: (2019)

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease
por: Macagno, Alban, et al.
Publicado: (2022)

Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy
por: Metz, Raphaël, et al.
Publicado: (2023)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment
por: Derlin, Thorsten, et al.
Publicado: (2021)

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
por: Willmann, Jonas, et al.
Publicado: (2022)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

An 87-year-old patient with repeated oligorecurrences over six years whose disease were treated with radiotherapy alone
por: Yun, Hyong Geun
Publicado: (2014)

Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs
por: Sherzay, Romilda, et al.
Publicado: (2021)

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?
por: Champion, Ambroise, et al.
Publicado: (2023)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2023)

Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy
por: Li, Minglun, et al.
Publicado: (2022)

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience
por: Oehler, Christoph, et al.
Publicado: (2019)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

Personalized prediction of mode of cardiac death in heart failure using supervised machine learning in the context of cardiac innervation imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

ShinyLUTS—A Shiny web application for structured data management and analysis for patients with lower urinary tract symptoms (LUTS)
por: von Klot, Christoph-Alexander Joachim, et al.
Publicado: (2023)

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
por: Karagiannis, Vasileios, et al.
Publicado: (2022)

(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Effectiveness of hypofractionated and normofractionated radiotherapy in a triple‐negative breast cancer model
por: Grosche, Sinja, et al.
Publicado: (2022)

Rezum water vapor thermal therapy for treatment of lower urinary tract symptoms: A retrospective single-centre analysis from a German high-volume centre
por: Winkler, Thorben, et al.
Publicado: (2023)

(18)F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
por: Derlin, Thorsten, et al.
Publicado: (2020)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nt5k61uia78jj668qmfcap3obl